Somewhere between half a percent and 2% of people worldwide have vitiligo, an autoimmune disorder that leads to the loss of skin pigmentation.
Over the summer, the Food and Drug Administration approved Ruxolitinib, a medicated cream used in clinical trials. It works by tamping down an overactive immune response.
In about one-third of vitiligo patients, Ruxolitinib showed extremely effective, according to a recent study.
Read the full article here.